Ieq Capital LLC Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Ieq Capital LLC raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,480 shares of the medical research company’s stock after purchasing an additional 4,528 shares during the quarter. Ieq Capital LLC’s holdings in Edwards Lifesciences were worth $5,771,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of EW. Vanguard Group Inc. grew its position in shares of Edwards Lifesciences by 1.1% during the first quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock worth $5,061,277,000 after buying an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after acquiring an additional 809,605 shares during the last quarter. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after acquiring an additional 393,109 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. Finally, Sands Capital Management LLC increased its position in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock worth $465,407,000 after purchasing an additional 1,567,526 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,250 shares of company stock worth $1,218,138. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $66.84 on Friday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average of $69.89 and a two-hundred day moving average of $82.86. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market capitalization of $40.28 billion, a price-to-earnings ratio of 28.81, a PEG ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company’s revenue was up 6.7% compared to the same quarter last year. During the same period last year, the company posted $0.66 EPS. As a group, analysts expect that Edwards Lifesciences Co. will post 2.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Oppenheimer reiterated an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Robert W. Baird lowered Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $102.00 to $70.00 in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their price target on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Citigroup lifted their price objective on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. Finally, Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $79.82.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.